PMID- 31855721
OWN - NLM
STAT- MEDLINE
DCOM- 20200709
LR  - 20200709
IS  - 1872-8421 (Electronic)
IS  - 0165-5728 (Linking)
VI  - 339
DP  - 2020 Feb 15
TI  - Antigen-specific immunoadsorption of MuSK autoantibodies as a treatment of 
      MuSK-induced experimental autoimmune myasthenia gravis.
PG  - 577136
LID - S0165-5728(19)30447-3 [pii]
LID - 10.1016/j.jneuroim.2019.577136 [doi]
AB  - Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular 
      junction. Approximately 9% of MG patients have autoantibodies targeting the 
      muscle specific kinase (MuSK), and are challenging therapeutically, since they 
      often present with more severe symptoms. A useful therapy is plasmapheresis, but 
      it is highly non-specific. Antigen-specific immunoadsorption would only remove 
      the pathogenic autoantibodies, minimizing the possible side effects and 
      maximizing the benefit. We used rats with human MuSK-induced experimental 
      autoimmune MG to perform antigen-specific immunoadsorptions, and found it very 
      effective, resulting in a dramatic autoantibody titer decrease, while 
      immunoadsorbed, but not mock-treated, animals showed an significant improvement 
      of their clinical symptoms. Overall, the procedure was efficient, supporting its 
      application for MG treatment.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Lazaridis, Konstantinos
AU  - Lazaridis K
AD  - Hellenic Pasteur Institute, Athens, Greece. Electronic address: 
      klazaridis@pasteur.gr.
FAU - Baltatzidou, Vasiliki
AU  - Baltatzidou V
AD  - Hellenic Pasteur Institute, Athens, Greece.
FAU - Tektonidis, Nikolaos
AU  - Tektonidis N
AD  - Hellenic Pasteur Institute, Athens, Greece.
FAU - Tzartos, Socrates J
AU  - Tzartos SJ
AD  - Hellenic Pasteur Institute, Athens, Greece; Tzartos NeuroDiagnostics, Athens, 
      Greece. Electronic address: stzartos@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191216
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (Autoantibodies)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Receptors, Cholinergic)
RN  - EC 2.7.10.1 (MUSK protein, human)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Animals
MH  - Autoantibodies/*administration & dosage/immunology
MH  - Female
MH  - Histocompatibility Antigens Class II/*administration & dosage/immunology
MH  - Humans
MH  - Immunization/methods
MH  - Myasthenia Gravis, Autoimmune, Experimental/*drug therapy/immunology
MH  - Plasmapheresis/*methods
MH  - Rats
MH  - Rats, Inbred Lew
MH  - Receptor Protein-Tyrosine Kinases/*administration & dosage/immunology
MH  - Receptors, Cholinergic/*administration & dosage/immunology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antibodies
OT  - Autoantibodies
OT  - Experimental autoimmune myasthenia gravis
OT  - Immunoadsorption
OT  - Muscle specific kinase
OT  - Myasthenia gravis
OT  - Therapy
EDAT- 2019/12/20 06:00
MHDA- 2020/07/10 06:00
CRDT- 2019/12/20 06:00
PHST- 2019/09/02 00:00 [received]
PHST- 2019/12/10 00:00 [revised]
PHST- 2019/12/11 00:00 [accepted]
PHST- 2019/12/20 06:00 [pubmed]
PHST- 2020/07/10 06:00 [medline]
PHST- 2019/12/20 06:00 [entrez]
AID - S0165-5728(19)30447-3 [pii]
AID - 10.1016/j.jneuroim.2019.577136 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2020 Feb 15;339:577136. doi: 10.1016/j.jneuroim.2019.577136. Epub 
      2019 Dec 16.